QuiaPEG

Newsroom

Feb 06, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops improved and patentable versions of clinically validated or already approved drugs using the company's unique technology platform, today announces that the company, in collaboration with a reputable global contract research company, has developed bioanalytical methods for the drug candidate QPG-1029 (PEG liraglutide) and the active drug substance liraglutide.

Download press release (PDF)
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message